Literature DB >> 15674342

HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.

Musaffe Tuna1, Arturo Chavez-Reyes, Ana M Tari.   

Abstract

High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression. Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells transfected with the HER2/neu oncogene than in parental MCF-7 cells. Conversely, inhibition of HER2/neu with the anti-HER2/neu trastuzumab (Herceptintrade mark) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and SKBr3 cells. We also found that HER2/neu engages Akt to regulate WT1 levels since inhibition of Akt reduced WT1 levels. Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and increased apoptosis in HER2/neu-overexpressing cells, which is correlated with decreased cyclin D1 and Bcl-2 levels. Our data indicate that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674342     DOI: 10.1038/sj.onc.1208345

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  The Wilms' tumor suppressor WT1 is associated with melanoma proliferation.

Authors:  Nicole Wagner; John Panelos; Daniela Massi; Kay-Dietrich Wagner
Journal:  Pflugers Arch       Date:  2007-10-03       Impact factor: 3.657

2.  The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.

Authors:  Lei Wang; Zhao-Yi Wang
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

3.  Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Authors:  Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.

Authors:  Kazuhiro Uesugi; Yoichi Hiasa; Yoshio Tokumoto; Toshie Mashiba; Yohei Koizumi; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-11-10       Impact factor: 7.527

Review 5.  Tumor Vaccines for Malignant Gliomas.

Authors:  Visish M Srinivasan; Sherise D Ferguson; Sungho Lee; Shiao-Pei Weathers; Brittany C Parker Kerrigan; Amy B Heimberger
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

6.  High-throughput Exploration of the Network Dependent on AKT1 in Mouse Ovarian Granulosa Cells.

Authors:  Maëva Elzaiat; Laetitia Herman; Bérangère Legois; Thibaut Léger; Anne-Laure Todeschini; Reiner A Veitia
Journal:  Mol Cell Proteomics       Date:  2019-04-16       Impact factor: 5.911

7.  Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.

Authors:  Mike Y Chen; Aaron J Clark; Dana C Chan; Joy L Ware; Shawn E Holt; Archana Chidambaram; Helen L Fillmore; William C Broaddus
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

8.  Pathway-based analysis of breast cancer.

Authors:  Dong Song; Miao Cui; Gang Zhao; Zhimin Fan; Katherine Nolan; Ying Yang; Peng Lee; Fei Ye; David Y Zhang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

9.  Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Authors:  Justin G Madson; David T Lynch; Jessica Svoboda; Rebecca Ophardt; Jodi Yanagida; Sumanth K Putta; Andrew Bowles; Carol S Trempus; Raymond W Tennant; Laura A Hansen
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

10.  A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.

Authors:  Zhiguo Chen; Wei Xie; Desmond Omane Acheampong; Menghuai Xu; Hua He; Mengqi Yang; Chenchen Li; Chen Luo; Min Wang; Juan Zhang
Journal:  Cancer Biol Ther       Date:  2015-12-15       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.